About OmerosPipelineInvestorsNews

Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.01 (0.05%)
Data as of 07/19/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
07/17/18Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
-- Nicotine Addiction Planned as First Indication -- SEATTLE--(BUSINESS WIRE)--Jul. 17, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitors of PDE7 have been demonstrated to modulate the brain’s ... 
 Printer Friendly Version
06/27/18Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
– First Clinical Target for PDE7 Inhibitor to be Nicotine Addiction – SEATTLE--(BUSINESS WIRE)--Jun. 27, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company’s OMS527 program. Omeros discovered the link between PDE7 and addiction, and the company holds broad patents ... 
 Printer Friendly Version
05/24/18Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
--Lupin Confirms Validity of OMIDRIA Patents-- SEATTLE--(BUSINESS WIRE)--May 24, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation against Lupin. The litigation concerned Lupin’s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Adminis... 
 Printer Friendly Version
05/10/18Omeros Corporation Reports First Quarter 2018 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE--(BUSINESS WIRE)--May 10, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include: 1Q 2018 total and OMIDRIA® revenues were $1.6 million, compared to $12.3 million in 1Q 2017; the decrease is the result of the scheduled expiration of OMIDRIA pass-throu... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation Corporate Presentation
Download Documentation 2017 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.